tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Dermata Reports Positive Phase 3 Trial Results
PremiumCompany AnnouncementsDermata Reports Positive Phase 3 Trial Results
2M ago
Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
Premium
The Fly
Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
2M ago
Dermata Therapeutics sees cash runway into 1Q26
Premium
The Fly
Dermata Therapeutics sees cash runway into 1Q26
2M ago
Dermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpoints
PremiumThe FlyDermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpoints
4M ago
Dermata Therapeutics announces last patient visit in Phase 3 acne trial
Premium
The Fly
Dermata Therapeutics announces last patient visit in Phase 3 acne trial
4M ago
Dermata Therapeutics receives notice of acceptance for Australian patent
Premium
The Fly
Dermata Therapeutics receives notice of acceptance for Australian patent
5M ago
Dermata Therapeutics to prices 2M shares at $1.27 in private placement
PremiumThe FlyDermata Therapeutics to prices 2M shares at $1.27 in private placement
6M ago
Dermata Therapeutics receives FDA approval for Xyngari proprietary name
Premium
The Fly
Dermata Therapeutics receives FDA approval for Xyngari proprietary name
7M ago
Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
Premium
The Fly
Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100